LOTTE BIOLOGICS is making significant strides in expanding its Contract Development and Manufacturing Organization (CDMO) capabilities by establishing state-of-the-art manufacturing facilities strategically located in North America and Asia. These new bases are set to enhance the company’s ability to cater to a broader range of biopharmaceutical clients, accelerating the delivery of complex biologics with improved efficiency and scalability. The move addresses the rising global demand for advanced biologics manufacturing, underlining LOTTE BIOLOGICS’ commitment to becoming a pivotal player in the global biopharma supply chain.

In addition to expanding geographic reach, LOTTE BIOLOGICS is pushing the boundaries of…